RESULTS

The patients were classified histopathologically into 5 groups of the following orders:

First group was patients with chronic active hepatitis representing 20% of cases. The second group was patients with post-hepatitic cirrhosis representing 24.4% of cases. Third group was patients with veno-occlusive disease representing 13.3% of cases. Fourth group was patients with pure bilharzial hepatic fibrosis representing 26.7% of cases. Where the fifth or last group was patients with hepatic bilharzial fibrosis associated with other hepatic lesions, (mixed type) which representing 15.6% of cases.

The clinical data for each group are shown as follows:

Group I : Normal control.

Group II : Chronic active group (table 1).

Group III : Post-hepatitic cirrhosis group (Table 2).

Group IV : Veno-occlusive group (Table 3).

Group V : Pure bilharzial fibrosis group (Table 4).

Group VI : Mixed group (Table 5).

Table 6 represents the percentage distributions of patients of the different groups.

The biochemical laboratory data are shown in Tables 7-12.

The mean values for the control group where estimated for the following parameters: Serum bilirubin, serum alkaline phosphatase, SGPT, SGOT, LDH and γ-GT, serum total proteins and protein electrophoresis as shown in Table 7.

The ratio of the results for the patients to those for the controls was estimated and accordingly each group had a mean ratio relative to the control(comparative Data) and presented in Tables 13a- 13 L.

The results are also presented diagramatically from Figures 1-13.

Fig. 1 shows that the mixed group had the heighest value of SGPT which is 7 folds that of normal. While in V.O.D. the increase was less than 1 fold or almost normal. In C.A.H. it was about 4.5 folds that of normal. Both P.H.C. & Schist. showed 2½ folds inorease than normal.

Fig.2 Shows that the SGOT values for patients with mixed group were so much increased (more than 12 folds that of normal) while V.O.D., cases showed the least increase (only 4.5 folds of normal).

The increase for C.A.H. was about 8 folds that of normal values. While P.H.C. & schist, groups were both increased with almost the same proportion of 5.5 folds.

Fig.3 showed that C.A.H. groups was the only group with total serum protein estimation higher than normal while all the other groups were less than normal or approximately similar to normal: V.O.D. had the least value below normal level.

Fig.4 showed that all groups had serum albumin lower than normal with cases of P.H.C. group having the least values amounting to nearly 50% of the normal level.

Fig.5 showed that the values for α_1 globulin estimation The group of pure schistosomiosis showed very slight decrease than normal level, while in V.O.D. the decrease was so prominent reaching about 90% of the normal level.

This was followed by P.H.C. group, the decrease than normal was about 75%.

The decrease in C.A.H. and mixed type was about 50% of the normal value.

Fig.6. illustrates the values for α_2 globulin protein fraction: only P.H.C. group showed values more than normal while all the other groups including schistosomiasis group were less than normal having approximately the same level except for schistosomiasis group whose values were more or less similar to normals.

Fig.7 showed that the B globulin fraction was decreased than normal by 30% only in cases of the mixed group.

Fig.8 the values for γ-globulin fraction is shown in Fig.8 C.A.H. group showed the highest elevation than normal (3 folds), while V.O.D. group was similar to normal.

The γ- globulin in cases of P.H.C. & schistesomiasis groups were increased by 2 folds.

The mixed group was increased by about 2.5 fold of normal inbetween C.A.H. on one side and both P.H.C. &

Table (1) : Chronic active hepatitis groups : Clinical Data

Serial number	Case number	History								Examination						Examination of the Liver							Clinical Diagnosis
		Age Year	Sex	Duration year	Jaundice	Anorexia	urinary Symptoms	Bleeding tendency	Abdominal distention	Weight Kgm	Jaundice	Oedema	Abdominal Veins	Ascites	Size of splenomegaly cm	Span cm	Midline cm	Nipple line cm	surface	consistancy	edge	Tendrness	
1	1	5¼	F	1	+	+	-	-	+	18	-	-	+	-	-	18	7	10	smooth	firm	round	No tend.	Hepatomegaly F.I
2	4	8½	M	2	+	+	-	-	++	23	-	+	+	+	5	13	5	7	Smooth	firm	sharp	No tend.	H.S.M. F
3	11	3½	M	1½	-	-	-	-	++	15	-	-	+	-	4	13	5	8	irreg.	firm	sharp	slight tend.	H.S.M. F
4	12	6	M	½	+	+	+	-	++	20	++	-	+	-	-	17	6	9	smooth	firm	round	slight tend.	Hepatomegaly F.I
5	20	11	M	4	+	+	+	-	++	32	+	-	-	-	-	16	6 cm	8	smooth	firm	sharp	No tend.	C.A.H.
6	21	8	M	11/12	+	+	+	-	++	25	+++	-	-	-	2	8	3	5	smooth	soft	round	tend.	C.A.H.
7	31	12	M	2	-	+	-	-	++	40	-	-	+	-	3	21	10	13	irreg.	firm	sharp	No tend.	H.S.M.
8	34	7	F	1/3	+	+	+	-	+	22	-	-	-	-	-	16	10	11	smooth	soft	round	tend.	C.A.H.
9	40	6	M	1/3	+	+	+	-	++	20	-	-	-	-	2	13	6	8	smooth	firm	round	tend.	C.A.H.
Number			M/F		7	8	5	-	9		3	1	5	1	5							5	4 cases
%			7/7 / 2/2		77.7	88.8	55.5		100		33.3	11.1	55.5	11.1	55.5							55.5	44.4
mean		7.5		1.4						23.8					3.2	15	6.4	8.7					Confirmed by the Liver biopsy
±S.D.		2.7		1.1						7.7					1.3	3.7	2.3						

Table (2) : Post hepatitic Cirrhosis group : Clinical Data

Serial number	Case number	History								Examination						Examination of the Liver							
		Age year	Sex	Duration year	Jaundice	Anorexia	urinary Symptoms	Bleeding tendency	Abdominal distention	Weight Kgm	Jaundice	Oedema	Abdominal Veins	Ascites	Size of splenomegaly Cm	Span cm	Midline cm	Nipple line cm	surface	consistancy	edge	Tendrness	Clinical Diagnosis
1	6	5	M	1	+	+	+	-	+	15	+	-	+	+	-	10	7	6	irreg.	firm	sharp	No tend.	C.A.H.
2	8	11	M	1 1/3	+	+	-	+	+	30	+	-	+	-	11	14	7	5	irreg.	firm	round	No tend.	H.S.M.F
3	13	8	M	2	+	+	+	+	++	27	++	-	++	+	10	6	2	1.5	smooth	firm	sharp	tend.	Portal v Thrombosi
4	19	7	M	2	-	++	+	-	+	23	±	-	++	++	5	10	5	6	irreg.	firm	sharp	No tend.	P.H.C. + Ascites
5	22	2	F	1	-	++	+	+	++	11	-	-	++	++	3	10	5	7	irreg.	firm	sharp	tend.	H.S.M. F.
6	24	5	M	1	+	+	+	-	+	18	+	-	-	+	5	8	4	3	irreg.	firm	sharp	tend.	P.H.C.
7	25	7	M	1/3	-	+	-	-	+	20	-	-	+	++	4	9	5	4	irreg.	firm	sharp	No tend.	H.S.M. F.
8	27	5	F	2½	+	+	+	+	++	17		+	++	+	5	10	7	5	irreg.	firm	sharp	tend.	H.S.M. F.
9	28	8	F	2	+	+	+	-	+	26	-	-	+	++	4	9	4	5	irreg.	firm	round	No tend.	C.A.H.
10	37	12	M	1	+	+	+	+	+	35	-	-	+	+	12	16	5	6	irreg.	firm	round	tend.	H.S.M. F.
11	44	6	M	2	+	+	+	-	+	19	-	-	+	+	10	18	6	7	irreg.	firm	sharp	No tend.	H.S.M. F.
number			M F		8	11	9	5	11		6	1	10	10	9							4	2 cases
%			72.7 27.3		72.7	100	81.8	45.5	100		54.5	9.1	90.9	90.9	81.8							36.3	18.18
mean	6.9			1½						21.9					6.9	10.9	5.2	5					Confirmed biopsy
±S.D.	2.8			0.6						7.1					3.4	3.6	1.5	1.7					

Table (3) : Veno-occlusive group : Clinical Data

Serial number	Case number	History								Examination						Examination of the Liver							Clinical Diagnosis
		Age Year	Sex	Duration Month	Jaundice	Anorexia	urinary Symptoms	Bleeding tendency	Abdominal distention	Weight Kgm.	Jaundice	Oedema	Abdominal Veins	Ascites	Size of splenomegaly	Span Cm.	Midline Cm.	Nipple line Cm.	surface	consistancy	edge	Tendrness	
1	2	3	M	3	-	-	-	-	+++	13	-	+	++	++	-	8	6	7	smooth	firm	sharp	No tend.	V.O.D.
2	14	6	M	2	+	+	-	+	+++	20	-	+	+++	+++	-	17	9	10	smooth	firm	sharp	No tend.	V.O.D.
3	17	2	F	2	-	+	-	-	++	13	+	-	+++	+	-	13	75	8	smooth	firm	sharp	tend.	V.O.D.
4	18	3½	M	4	-	-	-	-	++	15	++	++	++	++	-	11	5	6	smooth	firm	sharp	tend.	V.O.D.
5	23	4	F	2	-	+	-	-	++	13	-	++	+++	+++	-	17	7	9	smooth	firm	sharp	No tend.	V.O.D.
6	30	4	F	3	-	-	+	-	+	16	-	-	-	+	-	11	5	6	smooth	firm	sharp	No tend.	Hepatomegaly F.I
Number			M/F		1	3	2	1	6		2	5	5	6								2	5 cases
%			50/50		16.7	50	33.3	16.7	100		33.3	83.3	83.3	100								33.3	83.3
mean		3.8		2.7						15						12.8	6.6	7.7					Confirmed by biopsy
±S.D.		1.3		0.8						2.8						3.6	1.6	1.6					

Table (4) Pure Bilharzial hepatic fibrosis group:Clinical Data .

Serial number	Case number	History								Examination						Examination of the Liver								Clinical Diagnosis
		Age year	Sex	Duration year	Jaundice	Anorexia	urinary Symptoms	Bleeding tendency	Abdominal distention	Weight Kgm.	Jaundice	Oedema	Abdominal Veins	Ascites	Size of splenomegaly Cm.	Span cm	Midline cm	Nipple line cm	surface	consistancy	edge	Tendrness	
1	3	7y	F	2/3	-	+	+	-	+	23	-	-	-	+	5	20	12	10	smooth	firm	sharp	No tend.	H.S.M. + Ascites F.I.
2	5	11	M	¼	+	+	+	+	++	32	+	-	-	-	1	13	4	7	smooth	firm	sharp	tend.	F.H.S.M.
3	10	12	F	4y	+	-	+	-	++	31	-	-	+	-	12	16	10	11	irreg.	firm	sharp	No tend.	H.S.M. F
4	15	12½	M	1¼	-	-	-	-	++	29½	+	++	+	++	4	14	6	7	smooth	firm	sharp	tend.	H.S.M. F.
5	16	6½	F	2	+	+	+	+	++	19	-	+	+	++	6	14	7	8	irreg.	firm	sharp	No tend.	Post. hepatiti
6	29	12	F	1	+	-	+	-	+	37	-	+	-	+	5	17	6	9	irreg.	firm	sharp	tend.	H.S.M. F.
7	32	8	M	1½	+	-	+	+	+	26	-	-	-	+	4	16	6	8	irreg.	firm	sharp	No tend.	H.S.M. F.
8	35	10	M	5/12	-	-	+	+	++	30	-	-	+	-	5	18	9	10	smooth	firm	sharp	tend.	H.S.M. F.
9	39	11	F	5	+	-	+	-	++	34	-	+	+	+	4	21	14	10	irreg.	firm	sharp	No tend	F H.S.M.
10	42	6	M	1/12	-	-	+	-	++	20½	-	+	+	-	3	11	4	6	smooth	firm	sharp	tend.	F H.S.M.
11	43	12	F	4	+	+	+	+	++	37	-	+	+	+	12	16	10	7	irreg.	firm	sharp	No tend.	F H.S.M.
12	45	8y	M	1/3	+	+	-	-	+	26	-	-	+	-	4	14	5	8	smooth	firm	round	No tend.	Metabolic
Number			M/F		8	5	10	5	12		2	6	8	7	12							5	4 cases
%			50/50		66.6	41.6	83.3	41.6	100		16.6	50	66.6	58.3	100							41.6	33.3
mean	9.7			1.8						28.8					5.4	15.8	7.75	8.4					Confirmed by biopsy
±S.D.	2.4			1.6						6					3.3	2.9	3.2	1.6					

Table (5) Bilharzial hepatic fibrosis with other hepatitis lesions :
Clinical Data .

Serial number	Case number	History								Examination						Examination of the Liver							Clinic
		Age	Sex	Duration	Jaundice	Anorexia	urinary Symptoms	Bleeding tendency	Abdominal distention	Weight	Jaundice	Oedema	Abdominal Veins	Ascites	Size of splenomegaly	Span	Midline	Nipple line	surface	consistancy	edge	Tendrness	Diagn
		years		years						Kgm.					cm.	cm.	cm.	cm.					
1	7	10	M	2	+	+	+	+	++	29.	+	-	+	+	5	17	8	6	irreg.	firm	round	tend.	H.S.M. F.
2	9	9.	M	1½	+	+	+	-	+	26½	+	-	-	-	4	11	6	4	irreg.	firm	round	tend.	H.H.S.M.
3	26	14.	M	1	+	+	+	-	+	45	+	-	-	+	8	15	8	10½	smooth	firm	sharp	No tend.	H.H.S.M.
4	33	10.	F	2	-	+	+	-	+	27.	+	+	+	+	5	17	10	9	irreg.	firm	round	No tend.	H.H.S.M.
5	36	11.	M	½	-	+	+	+	++	30	+	+	+	+	4	20	9	11.	irreg.	firm	sharp	No tend.	H.H.S.M.
6	38	10	M	1.	-	-	+	-	+	29	-	-	+	-	5	15½	12	8	irreg.	firm	sharp	No tend.	H.S.M. F.
7	41	8.	M	1	-	+	+	+	+	22	-	-	-	+	3	13	4	6	irreg.	firm	sharp	No tend.	H.H.S.M.
Number			M/F		3	6	7	3	7		5	2	4	5	7							2	
%			85.7/14.3		42.9	85.7	100	42.9	100		71.4	28.5	57	71.4	100							28.5	
mean		10.1		1.3						29½					4.9	15.5	8.1	7.8					
±S.D.		1.9		0.6						7.3					1.6	2.9	2.6	2.6					

Table 6 : % of different groups

Groups of Diseases	No. of cases of		% Total No. of Cases of each group
	males	Females	
C.A.H.	7	2	20%
Post hepatitic Cirrhosis	8	3	24.4 %
V.O.D.	3	3	13.3 %
Pure bilharzial hepatic fibrosis	6	6	26.7 %
Mixed type	6	1	15.6 %

Table (7) group I Control cases

No	Sex	Virus	Serum	Serum Enzymes				Seram Proteins					
		Study	Bilirubin	ALK.P.	SGPT	SGOT	LDH	G.GT	Total	Alb.	α_1	α_2	B	γ
1	M	-Ve	0.5	70	9	7	200	10	7.3	4.5	0.2	0.5	0.9	1.2
2	M	-Ve	0.2	55	8	9	150	12	6.9	4.2	0.2	0.4	0.9	1.2
3	F	-Ve	0.2	50	5	4	100	9	7.1	3.9	0.2	0.9	1	1.1
4	M	-Ve	0.6	60	11	10	180	21	7	4.2	0.3	0.4	0.9	1.2
5	F	-Ve	0.7	65	7	9	200	19	6.6	4	0.1	0.7	0.8	1
6	M	-Ve	1	67	9	8	150	15	7	4.4	0.2	0.5	0.9	1
7	M	-Ve	0.8	44	6	7	190	11	7.5	4.2	0.3	0.8	1	1.2
8	M	-Ve	0.9	36	7	9	200	13	8	4.7	0.3	0.9	1	1.1
9	F	-Ve	0.7	40	8	10	210	10	7.1	4.2	0.2	0.8	0.9	1
10	M	-Ve	0.5	60	9	11	225	15	7.5	4.5	0.3	0.9	9.7	1.1
11	M	-Ve	0.9	50	10	9	240	18	6.8	3.8	0.3	0.6	1	1.1
12	M	-Ve	1	57	8	10	240	15	7.3	4.1	0.3	0.9	1	1
13	M	-Ve	0.4	45	8	6	170	9	6.5	3.9	0.3	0.5	1	0.8
14	F	-Ve	0.7	51	9	7	230	12	6.9	4.3	0.2	0.6	0.9	0.9
15	M	-Ve	0.4	30	5	9	150	8	7.6	4.6	0.3	0.8	0.8	1.1
mean			0.63	52	7.93	8.3	189	13.13	7.14	4.23	0.25	0.68	0.91	1.07
S.D.$\mp$			0.26	11.60	1.70	1.83	39.56	3.944	0.39	0.26	0.06	0.18	0.09	0.118

Table (8) group (II) patients with chronic Active hepatitis

No	Sex	Virus	Serum	Serum Enzymes					Seram Proteins					
		Study	Bilirubin	ALK.P.	SGPT	SGOT	LDH	G.GT	Total	Alb.	α_1	α_2	B	γ
1	F	-Ve	0.7	39	40	90	350	30	8.7	3.2	0.1	0.5	1.4	3.5
2	M	-Ve	1.0	66	21.75	75	452	57	7.3	3	0.1	0.4	0.8	3.0
3	M	-Ve	0.8	76	395	77.25	1250	29	8	3.4	0.1	0.6	0.5	3.4
4	M	+Ve	2.2	52	245	34.5	350	25	8.1	3.0	0.1	0.7	1.3	3.0
5	M	+Ve	1.0	89	4.6	65	562	26	7.6	3.1	0.1	0.5	1.3	2.6
6	M	+Ve	3.3	128	435	75	1300	80	8	3.2	0.1	0.5	1.3	2.9
7	M	-Ve	0.8	80	39	80	360	34	8	3.0	0.1	0.6	1.3	3
8	F	-Ve	1	90	24	60	400	35	7.5	3.0	0.1	0.5	0.8	3.1
9	M	-Ve	0.9	89	30	70	280	30	7.9	3.0	0.1	0.5	1.3	3
Mean			1.3	78.77	34.25	69.64	589.3	38.44	7.9	3.1	0.1	0.53	1.11	3.055
S.D.$\mp$			0.87	25.57	9.22	15.75	396.83	18.26	0.406	0.141	0	0.087	0.32	0.205

Table(9) Group (III) Patients with Post hepatitic Cirrhosis

No	Sex	Virus Study	Serum Bilirubin	Serum Enzymes ALK.P.	SGPT	SGOT	LDH	G.GT	Seram Proteins Total	Alb.	α_1	α_2	B	γ
1	M	-Ve	2	54	18.5	53	334	35	6.6	2.1	0.08	1.0	1.2	2.22
2	M	-Ve	1.7	115	25	60	350	55	6.8	2.3	0.09	1.0	1.3	2.11
3	M	-Ve	3.0	99	13	33	452	59	6.4	2.0	0.09	0.9	1.0	2.41
4	M	+Ve	0.7	54	13	47	360	25	7.7	2.5	0.09	1.1	1.3	2.71
5	F	+Ve	1.1	19	17	43	300	17	6.5	2.0	0.08	1.0	1.2	2.22
6	M	-Ve	2.8	105	25	60	450	42	6.9	2.5	0.08	1.0	1.2	2.12
7	M	-Ve	0.7	33.8	12	28	290	46	6.3	2.1	0.07	0.9	1.0	2.23
8	F	-Ve	5.5	118	38	73	400	103	5.6	2.1	0.07	0.5	0.6	2.33
9	F	-Ve	0.9	10	19	45	310	23	6.5	2.3	0.08	0.5	1.3	2.32
10	M	+Ve	1.0	95	18	25	250	30	6.8	2.2	0.09	1.0	1.2	2.31
11	M	+Ve	0.8	100	15	30	300	40	6.4	2.0	0.08	1.0	1.3	2.02
mean			1.8	72.98	19.4	45.18	345	43.18	6.59	2.19	0.08	0.9	1.145	2.27
S.D.$\pm$			1.467	39.805	7.57	15.37	65.72	23.77	0.51	0.18	0.01	0.2	0.21	0.18

Table(10) : Group (IV) Patients with Venoocclusive Disease

No	Sex	Virus	Serum	Serum Enzymes					Seram Proteins					
		Study	Bilirubin	ALK.P.	SGPT	SGOT	LDH	G.GT	Total	Alb.	α_1	α_2	B	γ
1	M	-Ve	1	90	7.5	41.5	480	45	5.8	3.0	0.05	0.6	0.9	1.25
2	M	-Ve	1	112	8	33	248	57	5.6	2.9	0.06	0.5	0.9	1.24
3	F	-Ve	1.2	116	11.75	41.5	296	60	6.0	3.1	0.05	0.45	1.2	1.2
4	M	-Ve	3	96	2.5	40	214	30	5.1	2.6	0.01	0.5	1.2	0.79
5	F	-Ve	1	97	8	25	250	32	5.6	2.9	0.01	0.6	1.3	0.79
6	F	-Ve	0.7	90	14	47	250	30	5.9	3	0.05	0.5	1.2	1.15
mean			1.3	100.16	8.6	38	289.6	42.3	5.67	2.92	0.03	0.53	1.11	1.07
S.D.$\mp$			0.840	11.17	3.955	7.79	96.82	13.75	0.320	0.172	0.02	0.06	0.17	0.219

Table(11) Group (V) Patients with **Bilharzial hepatic fibrosis.**

No	Sex	Virus	Serum	Serum Enzymes					Seram Proteins					
		Study	Bilirubin	ALK.P.	SGPT	SGOT	LDH	G.GT	Total	Alb.	α_1	α_2	B	γ
1	F	-Ve	0.5	81	18.8	42.5	248	40	6.4	2.5	0.3	0.9	1.1	1.6
2	M	-Ve	3	93	43.5	55	366	45	6.0	3.0	0.2	0.4	0.6	1.8
3	F	-Ve	1.2	40	33	58	1718	47	6.3	2.9	0.2	0.5	0.6	2.1
4	M	-Ve	2	162	27	80	310	70	6.5	2.7	0.2	0.6	0.7	2.3
5	F	-Ve	1	90	14.5	25.25	214	39	7	2.3	0.3	0.9	1.1	2.4
6	F	-Ve	0.4	42	13.8	33	209	36	6.5	2.5	0.2	0.9	1	1.9
7	M	-Ve	0.7	90	14	22	300	35	7.2	2.9	0.2	0.6	0.9	2.6
8	M	-Ve	1	80	19	30	280	37	7.5	3.1	0.2	0.6	0.9	2.7
9	F	-Ve	1.2	60	15	35	350	40	6.9	2.9	0.2	0.7	1.0	2.1
10	M	-Ve	0.5	95	20	45	360	32	7.3	3	0.3	0.5	1.1	2.4
11	F	-Ve	0.9	70	17	34	290	44	6.5	2.4	0.2	0.6	1	2.3
12	M	-Ve	0.8	104	25	55	380	33	7.2	3.4	0.2	0.5	0.9	2.2
mean			1.1	83.9	21.72	42.89	418.75	41.5	6.78	2.8	0.23	0.6	0.9	2.2
S.D.$\mp$			0.73	31.98	9.05	16.66	413.11	10.12	0.469	0.32	0.04	0.17	0.17	0.32

Table (12) group (VI) patients with mixed aetiologies (Bilhorzial hepatic fibrosis+ other lesions).

No	Sex	Virus	Serum	Serum Enzymes				Seram Proteins					
		Study	Bilirubin	ALK.P.	SGPT	SGOT	LDH	G.GT	Total	Alb.	α_1	α_2	B	γ
1	M	+Ve	1.7	82	130	150	600	68	6.6	2.9	0.2	0.1	0.5	2.9
2	M	-Ve	1.3	85	60	171	1200	45	8	3	0.1	0.6	0.8	3.5
3	M	-Ve	2.2	97.8	52	77	350	53	7	2.6	0.2	0.7	0.6	2.9
4	F	-Ve	1	90	40	90	300	40	6.5	2.8	0.2	0.5	0.8	2.2
5	M	-Ve	0.9	101	50	80	250	36	6.9	3.0	0.1	0.6	0.9	2.3
6	M	-Ve	0.7	89	60	100	260	38	7	3.1	0.2	0.7	0.8	2.2
7	M	+Ve	1.1	92	35	70	280	41	6.6	2.9	0.1	0.6	0.6	2.4
mean			1.27	90.9	61	105	462.8	45.86	6.94	2.9	0.15	0.54	0.71	2.03
S.D.$\mp$			0.518	6.698	31.83	39.29	346.73	11.24	0.50	0.16	0.05	0.20	0.14	0.489

Table $(13\text{-}a)_1$

AN VALUE OF SBILR. IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE

o.	MEAN	+ S.D.	S.E.	t	P
	2.06349	+ 1.3865	.4620		
	2.91486	+ 2.32882	.7022	1.013	N.S.
	2.08995	+ 1.33340	.5443	.0370	N.S.
	1.7463	+ 1.16838	.3373	.5550	N.S.
	2.01814	+ .823330	.3112	.0814	N.S.

654 - 660 No. 11

Table $(13\text{-}a)_2$

MEAN VALUE OF SBILR. IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
P H CIRR.	11	2.91486	+ 2.32882	.7022		
CH.ACTIVE	9	2.06349	+ 1.3865	.4620	1.013	N.S.
VENO-OC.	6	2.08995	+ 1.33340	.5443	.9285	N.S.
BILH. FIB	12	1.7463	+ 1.16838	.3373	1.50	N.S.
MIXED	7	2.01814	+ .823330	.3112	1.167	N.S.

Table $(13\text{-}a)_3$

MEAN VALUE OF SBILR. IN DIFFERENT GROUPS COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	2.08995	+ 1.33340	.5443		
CH.ACTIVE	9	2.06349	+ 1.3865	.4620	.0370	N.S.
P H CIRR.	11	2.91486	+ 2.32882	.7022	.9285	N.S.
BILH. FIB	12	1.7463	+ 1.16838	.3373	.5370	N.S.
MIXED	7	2.01814	+ .823330	.3112	.1145	N.S.

Table $(13\text{-}a)_4$

MEAN VALUE OF SBILR. IN DIFFERENT GROUPS COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	1.7463	+ 1.16838	.3373		
CH.ACTIVE	9	2.06349	+ 1.3865	.4620	.5550	N.S.
P H CIRR.	11	2.91486	+ 2.32882	.7022	1.50	N.S.
VENO-OC.	6	2.08995	+ 1.33340	.5443	.5370	N.S.
MIXED	7	2.01814	+ .823330	.3112	.5929	N.S.

Table $(13\text{-}b)_1$

MEAN VALUE OF ALK.PH IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
CH.ACTIVE	9	1.51496	+ .491682	.1639		
P H CIRR.	11	1.40350	+ .765511	.238	.3937	N.S.
VENO-OC.	6	1.92628	+ .214978	.0878	2.212	.0437
BILH. FIB	12	1.61378	+ .615136	.1776	.4090	N.S.
MIXED	7	1.74945	+ .128821	.0487	1.371	N.S.

Table$(13\text{-}b)_2$

MEAN VALUE OF ALK.PH IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
P H CIRR.	11	1.40350	+ .765511	.238		
CH.ACTIVE	9	1.51496	+ .491682	.1639	.3937	N.S.
VENO-OC.	6	1.92628	+ .214978	.0878	2.117	.0493
BILH. FIB	12	1.61378	+ .615136	.1776	.7221	N.S.
MIXED	7	1.74945	+ .128821	.0487	1.466	N.S.

MEAN VALUE OF ALK.PH IN DIFFERENT GROUPS
COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	1.92628	+ .214978	.0878		
CH.ACTIVE	9	1.51496	+ .491682	.1639	2.212	.0437
P H CIRR.	11	1.40350	+ .765511	.238	2.117	.0493
BILH. FIB	12	1.61378	+ .615136	.1776	1.578	N.S.
MIXED	7	1.74945	+ .128821	.0487	1.762	N.S.

Table(13-b)$_4$

MEAN VALUE OF ALK.PH IN DIFFERENT GROUPS
COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	1.61378	+ .615136	.1776		
CH.ACTIVE	9	1.51496	+ .491682	.1639	.4090	N.S.
P H CIRR.	11	1.40350	+ .765511	.238	.7221	N.S.
VENO-OC.	6	1.92628	+ .214978	.0878	1.578	N.S.
MIXED	7	1.74945	+ .128821	.0487	.7368	N.S.

Table $(13\text{-}C)_1$

MEAN VALUE OF SGPT IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
CH.ACTIVE	9	4.3194	+ 1.16368	.3879		
P H CIRR.	11	2.44755	+ .95493	.2879	3.874	.0010
VENO-OC.	6	1.08764	+ .498766	.2036	7.376	<.0001
BILH. FIB	12	2.73854	+ 1.14129	.3295	3.15	.0053
MIXED	7	7.69231	+ 4.01490	1.517	2.154	.0472

Table$(13\text{-}c)_2$

MEAN VALUE OF SGPT IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
P H CIRR.	11	2.44755	+ .95493	.2879		
CH.ACTIVE	9	4.3194	+ 1.16368	.3879	3.874	.0010
VENO-OC.	6	1.08764	+ .498766	.2036	3.856	.0015
BILH. FIB	12	2.73854	+ 1.14129	.3295	.6651	N.S.
MIXED	7	7.69231	+ 4.01490	1.517	3.396	.0034

Table (13-c)$_3$

MEAN VALUE OF SGPT IN DIFFERENT GROUPS COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	1.08764	+ .498766	.2036		
CH.ACTIVE	9	4.3194	+ 1.16368	.3879	7.376	<.0001
P H CIRR.	11	2.44755	+ .95493	.2879	3.856	.0015
BILH. FIB	12	2.73854	+ 1.14129	.3295	4.262	.006
MIXED	7	7.69231	+ 4.01490	1.517	4.314	.0012

Table (13-c)$_4$

MEAN VALUE OF SGPT IN DIFFERENT GROUPS COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	2.73854	+ 1.14129	.3295		
CH.ACTIVE	9	4.3194	+ 1.16368	.3879	3.15	.0053
P H CIRR.	11	2.44755	+ .95493	.2879	.6651	N.S.
VENO-OC.	6	1.08764	+ .498766	.2036	4.262	.006
MIXED	7	7.69231	+ 4.01490	1.517	3.190	.0050

Table (13-D)$_1$

MEAN VALUE OF SGOT IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE - - -

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
CH.ACTIVE	9	8.39023	+ 1.89861	.6329		
P H CIRR.	11	5.44359	+ 1.85230	.5585	3.491	.0024
VENO-OC.	6	4.57831	+ .938677	.3832	5.152	.002
BILH. FIB	12	5.16817	+ 2.00824	.5797	3.754	.0012
MIXED	7	12.7022	+ 4.73411	1.789	2.272	.0377

Table(13-D)$_2$

MEAN VALUE OF SGOT IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
P H CIRR.	11	5.44359	+ 1.85230	.5585		
CH.ACTIVE	9	8.39023	+ 1.89861	.6329	3.491	.0024
VENO-OC.	6	4.57831	+ .938677	.3832	1.277	N.S.
BILH. FIB	12	5.16817	+ 2.00824	.5797	.3421	N.S.
MIXED	7	12.7022	+ 4.73411	1.789	3.872	.0013

Table((13-D))$_3$

MEAN VALUE OF SGOT IN DIFFERENT GROUPS
COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	4.57831	+ .938677	.3832		
CH.ACTIVE	9	8.39023	+ 1.89861	.6329	5.152	.002
P H CIRR.	11	5.44359	+ 1.85230	.5585	1.277	N.S.
BILH. FIB	12	5.16817	+ 2.00824	.5797	.8488	N.S.
MIXED	7	12.7022	+ 4.73411	1.789	4.439	.0010

Table((13-D))$_4$

MEAN VALUE OF SGOT IN DIFFERENT GROUPS
COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	5.16817	+ 2.00824	.5797		
CH.ACTIVE	9	8.39023	+ 1.89861	.6329	3.754	.0012
P H CIRR.	11	5.44359	+ 1.85230	.5585	.3421	N.S.
VENO-OC.	6	4.57831	+ .938677	.3832	.8488	N.S.
MIXED	7	12.7022	+ 4.73411	1.789	4.05	.008

Table $(13\text{-}e)_1$

MEAN VALUE OF LDH IN DIFFERENT GROUPS COMPARED TO CH.ACTIVE

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
CH.ACTIVE	9	3.11816	+ 2.09965	.6999		
P H CIRR.	11	1.82588	+ .347740	.1048	1.826	N.S.
VENO-OC.	6	1.53263	+ .51231	.2091	2.170	.0472
BILH. FIB	12	2.21561	+ 2.18581	.6310	.9578	N.S.
MIXED	7	2.44898	+ 1.83457	.6934	.6792	N.S.

Table$(13\text{-}e)_2$

MEAN VALUE OF LDH IN DIFFERENT GROUPS COMPARED TO P H CIRR.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
P H CIRR.	11	1.82588	+ .347740	.1048		
CH.ACTIVE	9	3.11816	+ 2.09965	.6999	1.826	N.S.
VENO-OC.	6	1.53263	+ .51231	.2091	1.253	N.S.
BILH. FIB	12	2.21561	+ 2.18581	.6310	.6093	N.S.
MIXED	7	2.44898	+ 1.83457	.6934	.8885	N.S.

Table(13-e)$_3$

MEAN VALUE OF LDH IN DIFFERENT GROUPS COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	1.53263	+ .51231	.2091		
CH.ACTIVE	9	3.11816	+ 2.09965	.6999	2.170	.0472
P H CIRR.	11	1.82588	+ .347740	.1048	1.253	N.S.
BILH. FIB	12	2.21561	+ 2.18581	.6310	1.027	N.S.
MIXED	7	2.44898	+ 1.83457	.6934	1.265	N.S.

Table(13-e)$_4$

MEAN VALUE OF LDH IN DIFFERENT GROUPS COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	2.21561	+ 2.18581	.6310		
CH.ACTIVE	9	3.11816	+ 2.09965	.6999	.9578	N.S.
P H CIRR.	11	1.82588	+ .347740	.1048	.6093	N.S.
VENO-OC.	6	1.53263	+ .51231	.2091	1.027	N.S.
MIXED	7	2.44898	+ 1.83457	.6934	.2489	N.S.

Table $(13\text{-}f)_1$

MEAN VALUE OF GGT IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
CH.ACTIVE	9	2.84142	+ 1.35030	.451		
P H CIRR.	11	3.19156	+ 1.7577	.5298	.5037	N.S.
VENO-OC.	6	3.12885	+ 1.01627	.4149	.4695	N.S.
BILH. FIB	12	3.06726	+ .748114	.2160	.4524	N.S.
MIXED	7	3.38929	+ .83122	.3142	.9981	N.S.

Table$(13\text{-}f)_2$

MEAN VALUE OF GGT IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
P H CIRR.	11	3.19156	+ 1.7577	.5298		
CH.ACTIVE	9	2.84142	+ 1.35030	.451	.5037	N.S.
VENO-OC.	6	3.12885	+ 1.01627	.4149	.0932	N.S.
BILH. FIB	12	3.06726	+ .748114	.2160	.2173	N.S.
MIXED	7	3.38929	+ .83122	.3142	.3210	N.S.

Table(13-f)$_3$

MEAN VALUE OF GGT IN DIFFERENT GROUPS COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	3.12885	+ 1.01627	.4149		
CH.ACTIVE	9	2.84142	+ 1.35030	.451	.4695	N.S.
P H CIRR.	11	3.19156	+ 1.7577	.5298	.0932	N.S.
BILH. FIB	12	3.06726	+ .748114	.2160	.1317	N.S.
MIXED	7	3.38929	+ .83122	.3142	.504	N.S.

Table(13-f)$_4$

MEAN VALUE OF GGT IN DIFFERENT GROUPS COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	3.06726	+ .748114	.2160		
CH.ACTIVE	9	2.84142	+ 1.35030	.451	.4524	N.S.
P H CIRR.	11	3.19156	+ 1.7577	.5298	.2173	N.S.
VENO-OC.	6	3.12885	+ 1.01627	.4149	.1317	N.S.
MIXED	7	3.38929	+ .83122	.3142	.8447	N.S.

Table $(13\text{-}g)_1$

MEAN VALUE OF TOT PRT IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
CH.ACTIVE	9	1.10644	+ .056891	.0190		
P H CIRR.	11	.923096	+ .070989	.0214	6.411	<.0001
VENO-OC.	6	.793651	+ .044876	.0183	11.86	<.0001
BILH. FIB	12	.948879	+ .065726	.0190	5.874	<.0001
MIXED	7	.972389	+ .071349	.0270	4.066	.0011

Table$(13\text{-}g)_2$

MEAN VALUE OF TOT PRT IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
P H CIRR.	11	.923096	+ .070989	.0214		
CH.ACTIVE	9	1.10644	+ .056891	.0190	6.411	<.0001
VENO-OC.	6	.793651	+ .044876	.0183	4.594	.003
BILH. FIB	12	.948879	+ .065726	.0190	.9014	N.S.
MIXED	7	.972389	+ .071349	.0270	1.432	N.S.

Table(13-g)$_3$

MEAN VALUE OF TOT PRT IN DIFFERENT GROUPS
COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	.793651	+ .044876	.0183		
CH.ACTIVE	9	1.10644	+ .056891	.0190	11.86	<.0001
P H CIRR.	11	.923096	+ .070989	.0214	4.594	.003
BILH. FIB	12	.948879	+ .065726	.0190	5.885	<.0001
MIXED	7	.972389	+ .071349	.0270	5.482	.002

Table(13-g)$_4$

MEAN VALUE OF TOT PRT IN DIFFERENT GROUPS
COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	.948879	+ .065726	.0190		
CH.ACTIVE	9	1.10644	+ .056891	.0190	5.874	<.0001
P H CIRR.	11	.923096	+ .070989	.0214	.9014	N.S.
VENO-OC.	6	.793651	+ .044876	.0183	5.885	<.0001
MIXED	7	.972389	+ .071349	.0270	.7130	N.S.

Table (13-h)$_1$

MEAN VALUE OF ALB. IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
CH.ACTIVE	9	.732860	+ .033433	.0111		
P H CIRR.	11	.517945	+ .044170	.0133	12.38	<.0001
VENO-OC.	6	.689519	+ .040719	.0166	2.166	.0477
BILH. FIB	12	.661938	+ .076770	.0222	2.859	.0093
MIXED	7	.685579	+ .03865	.0146	2.575	.029

Table(13-h)$_2$

MEAN VALUE OF ALB. IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
P H CIRR.	11	.517945	+ .044170	.0133		
CH.ACTIVE	9	.732860	+ .033433	.0111	12.38	<.0001
VENO-OC.	6	.689519	+ .040719	.0166	8.055	<.0001
BILH. FIB	12	.661938	+ .076770	.0222	5.569	<.0001
MIXED	7	.685579	+ .03865	.0146	8.485	<.0001

Table(13-h)$_3$

MEAN VALUE OF ALB. IN DIFFERENT GROUPS COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	.689519	+ .040719	.0166		
CH.ACTIVE	9	.732860	+ .033433	.0111	2.166	.0477
P H CIRR.	11	.517945	+ .044170	.0133	8.055	<.0001
BILH. FIB	12	.661938	+ .076770	.0222	.9956	N.S.
MIXED	7	.685579	+ .03865	.0146	.1781	N.S.

Table(13-h)$_4$

MEAN VALUE OF ALB. IN DIFFERENT GROUPS COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	.661938	+ .076770	.0222		
CH.ACTIVE	9	.732860	+ .033433	.0111	2.859	.0093
P H CIRR.	11	.517945	+ .044170	.0133	5.569	<.0001
VENO-OC.	6	.689519	+ .040719	.0166	.9956	N.S.
MIXED	7	.685579	+ .03865	.0146	.8910	N.S.

Table (13- i)$_1$

MEAN VALUE OF @1 IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
CH.ACTIVE	9	.4	+ 0	0		
P H CIRR.	11	.327273	+ .030030	.0090	8.032	<.0001
VENO-OC.	6	.153333	+ .089144	.0364	6.778	<.0001
BILH. FIB	12	.9	+ .18097	.0522	9.574	<.0001
MIXED	7	.628571	+ .21389	.088	2.828	.0127

Table(13-i)$_2$

MEAN VALUE OF @1 IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
P H CIRR.	11	.327273	+ .030030	.0090		
CH.ACTIVE	9	.4	+ 0	0	8.032	<.0001
VENO-OC.	6	.153333	+ .089144	.0364	4.638	.003
BILH. FIB	12	.9	+ .18097	.0522	10.80	<.0001
MIXED	7	.628571	+ .21389	.088	3.75	.0018

Table(13-i)$_3$

MEAN VALUE OF ∅1 IN DIFFERENT GROUPS COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	.153333	+ .089144	.0364		
CH.ACTIVE	9	.4	+ 0	0	6.778	<.0001
P H CIRR.	11	.327273	+ .030030	.0090	4.638	.003
BILH. FIB	12	.9	+ .18097	.0522	11.73	<.0001
MIXED	7	.628571	+ .21389	.088	5.362	.002

Table(13-i)$_4$

MEAN VALUE OF ∅1 IN DIFFERENT GROUPS COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	.9	+ .18097	.0522		
CH.ACTIVE	9	.4	+ 0	0	9.574	<.0001
P H CIRR.	11	.327273	+ .030030	.0090	10.80	<.0001
VENO-OC.	6	.153333	+ .089144	.0364	11.73	<.0001
MIXED	7	.628571	+ .21389	.088	2.821	.0110

Table(13-J)$_1$

MEAN VALUE OF @2 IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE

GROUP	No.	MEAN	+	S.D.	S.E.	t	P
CH.ACTIVE	9	.784314	+	.127357	.0424		
P H CIRR.	11	1.32353	+	.301381	.099	5.376	<.0001
VENO-OC.	6	.75984	+	.11072	.0452	.3953	N.S.
BILH. FIB	12	.943627	+	.254391	.0734	1.878	N.S.
MIXED	7	.798319	+	.304441	.1151	.1142	N.S.

Table(13-J)$_2$

MEAN VALUE OF @2 IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+	S.D.	S.E.	t	P
P H CIRR.	11	1.32353	+	.301381	.099		
CH.ACTIVE	9	.784314	+	.127357	.0424	5.376	<.0001
VENO-OC.	6	.75984	+	.11072	.0452	5.555	<.0001
BILH. FIB	12	.943627	+	.254391	.0734	3.252	.0035
MIXED	7	.798319	+	.304441	.1151	3.582	.0023

Table(13-J)$_3$

MEAN VALUE OF ∅2 IN DIFFERENT GROUPS COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	.75984	+ .11072	.0452		
CH.ACTIVE	9	.784314	+ .127357	.0424	.3953	N.S.
P H CIRR.	11	1.32353	+ .301381	.099	5.555	<.0001
BILH. FIB	12	.943627	+ .254391	.0734	2.132	.0467
MIXED	7	.798319	+ .304441	.1151	.3115	N.S.

Table(13-J)$_4$

MEAN VALUE OF ∅2 IN DIFFERENT GROUPS COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	.943627	+ .254391	.0734		
CH.ACTIVE	9	.784314	+ .127357	.0424	1.878	N.S.
P H CIRR.	11	1.32353	+ .301381	.099	3.252	.0035
VENO-OC.	6	.75984	+ .11072	.0452	2.132	.0467
MIXED	7	.798319	+ .304441	.1151	1.064	N.S.

Table $(13\text{-}K)_1$

MEAN VALUE OF B IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE

GROUP	No.	MEAN	+	S.D.	S.E.	t	P
CH.ACTIVE	9	1.2210	+	.353722	.1179		
P H CIRR.	11	1.25874	+	.23245	.071	.2751	N.S.
VENO-OC.	6	1.22711	+	.189275	.0773	.0433	N.S.
BILH. FIB	12	.998168	+	.201314	.0581	1.695	N.S.
MIXED	7	.784929	+	.160863	.068	3.287	.0051

Table$(13\text{-}K)_2$

MEAN VALUE OF B IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+	S.D.	S.E.	t	P
P H CIRR.	11	1.25874	+	.23245	.071		
CH.ACTIVE	9	1.2210	+	.353722	.1179	.2751	N.S.
VENO-OC.	6	1.22711	+	.189275	.0773	.3033	N.S.
BILH. FIB	12	.998168	+	.201314	.0581	2.862	.0085
MIXED	7	.784929	+	.160863	.068	5.17	.001

Table(13-K)$_3$

MEAN VALUE OF B IN DIFFERENT GROUPS COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	1.22711	+ .189275	.0773		
CH.ACTIVE	9	1.2210	+ .353722	.1179	.0433	N.S.
P H CIRR.	11	1.25874	+ .23245	.071	.3033	N.S.
BILH. FIB	12	.998168	+ .201314	.0581	2.368	.0292
MIXED	7	.784929	+ .160863	.068	4.497	.009

Table(13-K)$_4$

MEAN VALUE OF B IN DIFFERENT GROUPS COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	.998168	+ .201314	.0581		
CH.ACTIVE	9	1.2210	+ .353722	.1179	1.695	N.S.
P H CIRR.	11	1.25874	+ .23245	.071	2.862	.0085
VENO-OC.	6	1.22711	+ .189275	.0773	2.368	.0292
MIXED	7	.784929	+ .160863	.068	2.535	.020

Table (13-L)$_1$

MEAN VALUE OF GAMA IN DIFFERENT GROUPS
COMPARED TO CH.ACTIVE

GROUP	No.	MEAN	+	S.D.	S.E.	t	P
CH.ACTIVE	9	2.85566	+	.247757	.0826		
P H CIRR.	11	2.1244	+	.171825	.0518	7.54	<.0001
VENO-OC.	6	1.	+	.205352	.0838	15.77	<.0001
BILH. FIB	12	2.0567	+	.300865	.0868	6.672	<.0001
MIXED	7	2.45661	+	.456939	.1727	2.084	N.S.

Table(13-L)$_2$

MEAN VALUE OF GAMA IN DIFFERENT GROUPS
COMPARED TO P H CIRR.

GROUP	No.	MEAN	+	S.D.	S.E.	t	P
P H CIRR.	11	2.1244	+	.171825	.0518		
CH.ACTIVE	9	2.85566	+	.247757	.0826	7.54	<.0001
VENO-OC.	6	1.	+	.205352	.0838	11.40	<.0001
BILH. FIB	12	2.0567	+	.300865	.0868	.6721	N.S.
MIXED	7	2.45661	+	.456939	.1727	1.844	N.S.

Table(13-L)$_3$

MEAN VALUE OF GAMA IN DIFFERENT GROUPS COMPARED TO VENO-OC.

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
VENO-OC.	6	1.	+ .205352	.0838		
CH.ACTIVE	9	2.85566	+ .247757	.0826	15.77	<.0001
P H CIRR.	11	2.1244	+ .171825	.0518	11.40	<.0001
BILH. FIB	12	2.0567	+ .300865	.0868	8.749	<.0001
MIXED	7	2.45661	+ .456939	.1727	7.587	<.0001

Table(13-L)$_4$

MEAN VALUE OF GAMA IN DIFFERENT GROUPS COMPARED TO BILH. FIB

GROUP	No.	MEAN	+ S.D.	S.E.	t	P
BILH. FIB	12	2.0567	+ .300865	.0868		
CH.ACTIVE	9	2.85566	+ .247757	.0826	6.672	<.0001
P H CIRR.	11	2.1244	+ .171825	.0518	.6721	N.S.
VENO-OC.	6	1.	+ .205352	.0838	8.749	<.0001
MIXED	7	2.45661	+ .456939	.1727	2.072	N.S.

C.A.H.= chronic active hepatitis

P.H.C. = Post-hepatitic cirrhosis

V.O.D. = Veno-occlusive disease

Schist.= Schistosomiasis

Mixed = Schistosomiasis + other lesions



Fig (1) : Bar chart showing the mean values of SGPT in different groups relative to the normal .



Fig. (2) : Bar chart showing the mean values of SGOT in different groups relative to the normal .



Fig. (3) : Bar chart showing the mean values of Serum total protein in different groups relative to the normal.

C.A.H. = chronic active hepatitis
P.H.C.=Post-hepatitic cirrhosis
V.O.D.= Veno-occlusive disease
Schist.= Schistosomiasis
Mixed = Schistosomiasis + other lesions



Fig. (4) : Bar chart showing the mean values of Serum albumin in different groups relative to the normal

C.A.H. = chronic active hepatitis
P.H.C. = Post-hepatitic cirrhosis
V.O.D. = Veno-occlusive disease
Schist.= Schistosomiasis
Mixed = Schistosomiasis + other lesions



Fig. (5) : Bar chart showing the mean values of Serum α_1 globulin in different groups relative to the normal



Fig. (6): Bar chart showing the mean values of Serum α_2 globulin in different groups

C.A.H. = chronic active hepatitis
P.H.C. = Post-hepatitic cirrhosis
V.O.D. = Veno-occlusive disease
Schist.= Schistosomiasis
Mixed = Schistosomiasis + other lesions



Fig. (7) :Bar chart showing the mean values of Serum B-globulin in different groups relative to the normal



Fig. (8): Bar chart showing the mean values of Serum gamma-globulin in different groups relative to the normal .



Fig. (9): Bar chart showing the mean values of different serum enzymes in C.A.H. group relative to the normal.



Fig. (10): Bar chart showing the mean values of different serum enzymes in P.H.C. group relative to the normal.



Fig. (11): Bar chart showing the mean values of different serum enzymes in V.O.D. group relative to the normal.



Fig. (12): Bar chart showing the mean values of different serum enzymes in pure Schist. group relative to the normal.



Fig. (13): Bar chart showing the mean values of different serum enzymes in Mixed group relative to the normal.



Fig. (14): chronic active hepatitis. Section in the liver showing fibrous septa extending into the liver cells columns with isolation of small groups of degenerating liver cells, and infiltrated by lymphocytes. A picture of chronic active hepatitis with bridging necrosis from case number 31. (Hx. and E. X 150) .



Fig.(15): Chronic active hepatitis.Section in the liver stained by PAS showing reticulin of fibrous septa extending into the liver cells colamns of the same patient of Fig. 14.(PAS stain X 150).



Fig.(16): Chronic active hepatitis.Section in the liver showing piecemeal necrosis and preportal infiltration by lymphocytes a picture of chronic active hepatitis , from a case number 4. (Hx. and E. X 125).



Fig. (17): Chrnoic active hepatitis. A widened portal tract with intense fibrosis and patchy mononuclear cell infiltration, hepatic parenchyma (left) shows inflammation with ballooning and piecemeal necrosis, a picture of chronic active hepatitis with piecemeal necrosis from case number 20. (Hx. and E. X 150).



Fig.(18): Post-hepatitic cirrhosis. Section in the liver showing a regenerating nodules surrounded by thick fibrous tissue with ballooning of hepatocytes and infiltered by chronic inflammatory cells, from case number 19. (Hx and E. X 90).



Fig.(19): Post hepatitic cirrhosis. Section in the liver of the same patient number 19 stained with PAS showing the fibrous tissue surrounding the nodule (PAS stain X 100).



Fig. (20) : Active post-hepatitic cirrhosis. A section in the liver showing a regenerating nodules surrounded by fibrous tissue and heavily infiltrated by inflammatory cells in the portzl tract, apicture of active, post-hepatitic cirrhosis, from a case number 27. (Hx. and E. X 90).



Fig. (21): Active post-hepatitic cirrhosis. The same view of the same patient number 27 with higher magnification. (Hx. and E. X 150).



Fig. (22): Veno-occlusive disease. Section in the liver showing moderate dilatation of the central veins and central sinusoids with evidence of congestion, mild hydropic degeneration of hepatocytes is present, from case number 14. (Hx. and E. x 250).



Fig. (23): Veno-occlusive disease. Section in the liver showing advanced dilatation of the central Veins and central sinusoids with evidence of (blood lagoons) and necrosis of the surrounding liver cells. From case number 18. (Hx. and E. x 250).



Fig.(24): Bilharzial liver. A Section in the liver showing bilharzial granuloma in the portal tract from case number 5.(Hx. and E. x 125).



Fig.(25): Bilharzial liver. A section in the liver showing bilharzial granuloma in the portal tract with foreign body giant cells and cellular infiltration around No. bilharzial ova seen in this section , from case number 29. (Hx. and E. 125).



Fig.(26):Bilharzial liver. A section in the liver showing bilharzial granuloma in the portal tract with preportal fibrosis and infiltration by chronic inflammatory cells, from case number 32.(Hx. and E. X 90).

Fig.(27):Bilharzial liver. A section in the



Fig.(28): Bilharzial liver. A section in the liver of bilharzial fibrosis showing fibrosis in the portal tract and proliferation of bile ducts; from case number 16. (Hx. and E. X 125).